Studies have shown that HER2 amplification or aberrant activation is closely correlated with an aggressive phenotype in HER2-positive breast cancer, often orientated toward high recurrence rates and poorer survival outcomes.[12,31,32] The research conducted by Tiwari et al uncovered that 88% (14 cases) of patients with HER2-amplified breast cancer had positive regional lymph nodes. The gene discussed is ERBB2; the disease is breast carcinoma.